Review of adult gender transition medications: mechanisms, efficacy measures, and pharmacogenomic considerations
Gender dysphoria is the imparity between a person’s experienced gender and their birth-assigned gender. Gender transition is the process of adapting a person’s sexual characteristics to match their experienced gender. The number of adults receiving sex hormone therapy for gender dysphoria is increas...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-07-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1184024/full |
| _version_ | 1797786636978749440 |
|---|---|
| author | Inder Sehgal |
| author_facet | Inder Sehgal |
| author_sort | Inder Sehgal |
| collection | DOAJ |
| description | Gender dysphoria is the imparity between a person’s experienced gender and their birth-assigned gender. Gender transition is the process of adapting a person’s sexual characteristics to match their experienced gender. The number of adults receiving sex hormone therapy for gender dysphoria is increasingly and these pharmacotherapies are increasing being prescribed in a general practice setting. The role of hormone therapy is to reverse or reduce physical sexual characteristics of the birth-assigned gender and enhance and build characteristics aligning to the expressed gender and these therapies apply to both transgender and gender nonconforming patients. Recognizing the options and interpreting the effects of gender transition therapies are fundamental to the discussion and treatment of gender dysphoria. This review summarizes pharmacodynamics, comparative dosing, adverse effects, monitoring, and potential pharmacogenetic influence of current pharmacotherapy. These include the use of 17-beta-estradiol, spironolactone, testosterone, GnRH agonists as well as adjunctive phosphodiesterase-5 inhibitors. The article also addresses gaps within the published literature including optimal routes of administration for individual patients, risks of malignancy and dosing reductions as transgender patients age. |
| first_indexed | 2024-03-13T01:11:43Z |
| format | Article |
| id | doaj.art-65f26356ba484b9ca5b7f8ffdda3b259 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-03-13T01:11:43Z |
| publishDate | 2023-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-65f26356ba484b9ca5b7f8ffdda3b2592023-07-05T22:04:30ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922023-07-011410.3389/fendo.2023.11840241184024Review of adult gender transition medications: mechanisms, efficacy measures, and pharmacogenomic considerationsInder SehgalGender dysphoria is the imparity between a person’s experienced gender and their birth-assigned gender. Gender transition is the process of adapting a person’s sexual characteristics to match their experienced gender. The number of adults receiving sex hormone therapy for gender dysphoria is increasingly and these pharmacotherapies are increasing being prescribed in a general practice setting. The role of hormone therapy is to reverse or reduce physical sexual characteristics of the birth-assigned gender and enhance and build characteristics aligning to the expressed gender and these therapies apply to both transgender and gender nonconforming patients. Recognizing the options and interpreting the effects of gender transition therapies are fundamental to the discussion and treatment of gender dysphoria. This review summarizes pharmacodynamics, comparative dosing, adverse effects, monitoring, and potential pharmacogenetic influence of current pharmacotherapy. These include the use of 17-beta-estradiol, spironolactone, testosterone, GnRH agonists as well as adjunctive phosphodiesterase-5 inhibitors. The article also addresses gaps within the published literature including optimal routes of administration for individual patients, risks of malignancy and dosing reductions as transgender patients age.https://www.frontiersin.org/articles/10.3389/fendo.2023.1184024/fulltransgendergender dysphoriapharmacogeneticshormonal therapyestradioltestosterone |
| spellingShingle | Inder Sehgal Review of adult gender transition medications: mechanisms, efficacy measures, and pharmacogenomic considerations Frontiers in Endocrinology transgender gender dysphoria pharmacogenetics hormonal therapy estradiol testosterone |
| title | Review of adult gender transition medications: mechanisms, efficacy measures, and pharmacogenomic considerations |
| title_full | Review of adult gender transition medications: mechanisms, efficacy measures, and pharmacogenomic considerations |
| title_fullStr | Review of adult gender transition medications: mechanisms, efficacy measures, and pharmacogenomic considerations |
| title_full_unstemmed | Review of adult gender transition medications: mechanisms, efficacy measures, and pharmacogenomic considerations |
| title_short | Review of adult gender transition medications: mechanisms, efficacy measures, and pharmacogenomic considerations |
| title_sort | review of adult gender transition medications mechanisms efficacy measures and pharmacogenomic considerations |
| topic | transgender gender dysphoria pharmacogenetics hormonal therapy estradiol testosterone |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2023.1184024/full |
| work_keys_str_mv | AT indersehgal reviewofadultgendertransitionmedicationsmechanismsefficacymeasuresandpharmacogenomicconsiderations |